Data are available via Figshare (DOI: [10.6084/m9.figshare.8299700](https://doi.org/10.6084/m9.figshare.8299700)).

Introduction {#sec005}
============

The use of grading scales to assess the presence and severity of ocular complications has increased in recent years. A survey of 237 Australian optometrists revealed that 61% of them employed grading scales in their daily routine \[[@pone.0226960.ref001]\], with a preference for the artistic Efron Grading Scales for Contact Lens Complications \[[@pone.0226960.ref002]\]. A second, global survey of 809 eye care practitioners, with a majority of optometrists, disclosed that 84.5% of respondents used grading scales to record ocular findings, with a 51.6% opting for the Efron scales and 48.5% for the Brien Holden Vision Institute scales (formerly known as CCRLU grading scales \[[@pone.0226960.ref003]\]), which consist of real photographs of ocular conditions \[[@pone.0226960.ref004]\]. Less recent surveys of UK and Australian ophthalmologists indicated lower rates of use of grading scales for the evaluation of cataract and pterygium, respectively \[[@pone.0226960.ref005],[@pone.0226960.ref006]\].

Currently, there are many grading scale options available to the clinician, from those assessing a variety of ocular conditions, both contact lens and non-contact lens related, to scales developed to grade specific disorders, such as lid wiper \[[@pone.0226960.ref007]\], corneal and conjunctival staining \[[@pone.0226960.ref008],[@pone.0226960.ref009]\] or Meibomian gland dysfunction \[[@pone.0226960.ref010]\], amongst others. In an attempt to avoid the intrinsic limitations of subjective grading, research efforts have been directed to developing objective grading techniques, mainly based on digital image processing \[[@pone.0226960.ref011]--[@pone.0226960.ref014]\]. However, objective grading techniques are commonly restricted to few ocular conditions, such as bulbar hyperaemia \[[@pone.0226960.ref011],[@pone.0226960.ref012]\] or corneal staining \[[@pone.0226960.ref013],[@pone.0226960.ref014]\], and are themselves not free of limitations.

Subjective grading of ocular complications is a relatively simple process involving the comparison of real live images, obtained using a slit-lamp, with a set of photographs or artistic drawings representing conditions at various degrees of severity. This process is modulated by the experience, training and knowledge of the observer \[[@pone.0226960.ref015]\]. In addition to good accuracy and reliability, subjective grading of ocular complications must also be free of bias. Biases have been known to challenge the objectivity of scientific research and, as such, efforts have been devoted to identify, classify and develop strategies to avoid, or at least critically appraise, the impact of biases \[[@pone.0226960.ref016]\]. An example of such an effort is the extensive, continuously updated catalogue of biases affecting medical evidence compiled by the Centre for Evidence Based Medicine at Oxford University (available at <https://catalogofbias.org/>). Of interest in subjective grading may be observer bias and misclassification bias. Observer bias refers to the effect of the predispositions or preconceptions of the observer, such as the documented predisposition of examiners to grade to the nearest whole number, even if the scale is divided in 0.1 increments \[[@pone.0226960.ref017],[@pone.0226960.ref018]\]. Misclassification bias, on the other hand, occurs when patients are erroneously assigned to a given category, and includes non-differential and differential misclassification bias, the later occurring when the probability of misclassification depends on the actual status of the patient \[[@pone.0226960.ref019],[@pone.0226960.ref020]\].

The aim of the present study was to explore differential misclassification bias as an additional source of bias in subjective grading of ocular complications. In particular, a possible source of bias defined as "awareness of treatment". A grading simulation, consisting of three grading sessions, was implemented to explore whether participants graded differently those conditions they were informed were following a successful treatment plan as compared to those left untreated.

Materials and methods {#sec006}
=====================

Subjects {#sec007}
--------

Optometry students from the Technical University of Catalonia were recruited for this study. Thirty students (17 females) participated in the study, with an age of 21.7±2.1 (mean ± SD) years, ranging from 21 to 32 years. All subjects were enrolled in the Basic Contact Lenses course, which is programmed in the fifth semester of the 4-year Optics and Optometry degree, and had passed the Ocular Pathology and Pharmacology courses, which are programmed in the fourth semester. All subjects had a basic knowledge of and experience with grading scales for ocular complications. Written informed consent was provided by all participants after the nature of the study was explained to them. In this regards, at the start of the study, subjects were only informed that they would be participating in three grading sessions. It was only following the conclusion of the third grading session that the full purpose of the study was explained, including the partial deceit required for the third grading session. The study was approved by an Institutional Review Board (Facultat d'Òptica I Optometria de Terrassa) (2018-07-27T06).

Ocular conditions and grading procedure {#sec008}
---------------------------------------

Three conditions, which may be contact lens or non-contact lens related, were selected for this study: bulbar hyperaemia, limbal vascularization and corneal staining. Photographs were obtained from a database of anterior segment images captured with the same Topcon SL-D7 slit-lamp and DL-4 5-megapixel digital camera (Topcon España S.A., Barcelona, Spain). For image capture, slit-lamp magnification was set at 10X and a circular light beam of 10 mm in diameter was employed to illuminate the ocular surface. To observe and photograph corneal staining, a cobalt blue light filter was used, in combination with a Wratten \#12 yellow filter (Kodak, Rochester, NY, US) positioned in front of the observation system of the slit-lamp. Twenty-four images (8 of each condition) were selected, aiming at a wide spectrum of disease severity, thus also including healthy eyes. At the time of the study, images did not include any type of identification linking them to the corresponding original patients.

The Efron Grading Scales for Contact Lens Complications were used. These scales, which are described in detail in the literature \[[@pone.0226960.ref002],[@pone.0226960.ref021]\], consist of 16 sets of artistic drawings that cover key anterior ocular complications of contact lens wear, illustrated in five stages of increasing severity from zero to four. The sets depicting bulbar hyperaemia, limbal vascularization and corneal staining were selected.

Subjects used copies of a printed vertical visual analogue scale (VVAS) to grade each of the conditions \[[@pone.0226960.ref022]\]. This scale consisted of a 100-millimetre vertical line with five markings on its length to designate grades 0 to 4 (that is, at 0, 25, 50, 75 and 100 mm, respectively). Next to each of these markings, the corresponding drawing from the Efron scale was presented to offer visual clues to assist in the grading process. Ocular images were displayed on a 24 inch, 16:9 liquid crystal display (TFT-LCD) set to a resolution of 1920 per 1080 pixels, 32-bit colour configuration, contrast ratio 700:1 and 75 Hz refresh rate. Room illumination conditions were constant throughout the grading sessions. Participants observed the images on the computer screen at a distance of approximately 50 centimetres.

After briefly explaining the grading process, each subject was asked to grade the 24 images. Participants had 30 seconds to grade each condition. Grades were assigned by marking the desired location on the VVAS. Grading scores were obtained by measuring the height of each mark on the VVAS. All measurements were conducted by a research assistant not aware of the purpose of the study.

Three grading sessions were scheduled, with a two-week interval between consecutive sessions. At each grading session, the same 24 images were graded, albeit in different, randomly generated, inter-session and inter-subject sequences of presentation. At the third and last grading session, subjects were deceptively informed that they would be grading the same patients as in the previous two sessions, but that some of them had been following a successful treatment plant, whereas the conditions of others were left untreated. Accordingly, each image was accompanied by a non-intrusive label indicating either "treated" or "untreated". For each subject and image, "treated" and "untreated" labels were assigned and presented randomly, with 12 images labelled as "treated" and the other 12 images as "untreated". To avoid conscious bias, the relevance of the label on the images was not stressed to the participants.

Data analysis {#sec009}
-------------

Statistical analysis of the data was performed with the IBM SPSS Statistics software 25.0 (IBM Corp., NY, US) for Windows. All data were examined for normality using the Kolmogorov-Smirnov test, which revealed normal distributions for most of the variables. A *p-value* of 0.05 or less was considered to denote statistical significance throughout the study.

Intraclass correlation coefficients (ICC) (two-way mixed effects, absolute agreement, multiple examiners/measurements model) of session 1 and 2 (test-retest) were calculated to determine grading reliability for each image and the corresponding median and range (minimum-maximum) of values for each ocular condition (comprised of 8 images) was determined. In addition, a Bland-Altman analysis was conducted by pooling test-retest data of the eight images of each type of condition. The mean difference (bias) and Limits of Agreement (LOA, defined as the mean difference ± 1.96 standard deviations of the mean difference) were determined, as well as the approximate 95% confidence limits for the LOAs, given a sufficiently large sample size (n = 240) \[[@pone.0226960.ref023],[@pone.0226960.ref024]\].

Finally, to explore grading bias resulting from "awareness of treatment", a paired Student's t-test was used to compare the mean grading differences of session 1 and 2 (test-retest) with those of session 1 and 3 (either "treated" or "untreated" status) for each ocular condition. Bland-Altman analysis was conducted to explore and display any systematic bias.

Results {#sec010}
=======

Grading reliability {#sec011}
-------------------

Average values and 95% confidence intervals of test-retest grading differences were 0.2 (-0.4 to 0.8) for bulbar hyperaemia, 0.0 (-0.7 to 0.7) for limbal vascularization and -0.1 (-0.6 to 0.4) for corneal staining. Median (minimum-maximum) ICC test-retest (session 1 and 2) values were 0.80 (0.62--0.84) for bulbar hyperaemia, 0.68 (0.65--0.77) for limbal vascularization and 0.68 (0.66--0.74) for corneal staining. Overall, higher ICC values corresponded to images displaying conditions located near the top or bottom thresholds of the grading scales. [**Fig 1A**, **1B** and **1C**](#pone.0226960.g001){ref-type="fig"} display the Bland-Altman analysis for each condition. Upper and lower LOA were 9.0 (95% CI 8.0 to 9.0) and -8.7 (95% CI -7.7 to -9.7) for bulbar hyperaemia, 10.3 (95% CI 9.2 to 11.5) and -10.4 (95% CI -9.2 to -11.5) for limbal vascularization and 8.9 (95% CI 7.9 to 9.9) and -9.2 (95% CI -8.2 to -10.2) for corneal staining. No noticeable systematic error was observed in grading of any of the three conditions under study. As with the ICC analysis, the Bland-Altman plots show less dispersion of the data towards both ends of the grading spectrum.

![Bland-Altman analysis of the test-retest grading sessions.\
**1a**. Bulbar hyperaemia. **1b**. Limbal vascularization. **1c**. Corneal staining. Mean test-retest difference (solid line) and lower and upper limits of agreement are shown (discontinuous lines).](pone.0226960.g001){#pone.0226960.g001}

Awareness of treatment {#sec012}
----------------------

Average values and 95% confidence intervals for grading differences between session 1 and session 3, when considering the "treated" conditions were -6.4 (-7.2 to -5.6) for bulbar hyperaemia, -4.5 (-5.1 to -3.9) for limbal vascularization and -3.6 (-4.7 to -2.4) for corneal staining. In contrast, average grading differences for conditions left "untreated" were 5.3 (4.4 to 6.2) for bulbar hyperaemia, 4.4 (3.7 to 5.1) for limbal vascularization and 3.8 (2.9 to 4.7) for corneal staining. Statistically significant outcomes were found between the average grading differences of session 1 and session 2 and those of session 1 and session 3 in bulbar hyperaemia "treated" (t = 16.336; p\<0.001) and "untreated" (t = -12.620; p\<0.001), limbal vascularization "treated" (t = 10.508; p\<0.001) and "untreated" (t = -9.926; p\<0.001) and corneal staining "treated" (t = 5.674; p\<0.001) and "untreated" (t = -9.759; p\<0.001). In all instances, in session 3, "treated" conditions were allocated smaller grading values and "untreated" conditions larger grading values than in session 1. The Bland-Altman analysis for each condition labelled as either "treated" or "untreated" is displayed in **[Fig 2](#pone.0226960.g002){ref-type="fig"}**. [**Fig 2A** and **2B**](#pone.0226960.g002){ref-type="fig"} correspond to bulbar hyperaemia, with upper and lower LOA values of 6.3 (95% CI 4.3 to 8.3) and -19.1 (95% CI --17.1 to -21.1) for "treated" conditions and of 14.8 (95% CI 13.3 to 16.3) and -4.2 (95% CI -2.7 to -5.7) for "untreated" conditions. Similarly, [**Fig 2C** and **2D**](#pone.0226960.g002){ref-type="fig"} display limbal vascularization, with upper and lower LOA values of 3.3 (95% CI 2.0 to 4.5) and -12.3 (95% CI -11.1 to -13.6) for "treated" conditions and of 16.3 (95% CI 14.5 to 18.2) and -7.3 (95% CI -5.4 to -9.2) for "untreated" conditions. Finally, [**Fig 2E** and **2F**](#pone.0226960.g002){ref-type="fig"} display the corresponding analysis for corneal staining, with LOA values of 7.5 (95% CI 5.7 to 9.2) and -14.6 (95% CI -12.8 to -16.3) for "treated" conditions and of 13.7 (95% CI 12.2 to 15.3) and -6.0 (95% CI -4.5 to -7.6) for "untreated" conditions. Negative and positive systematic errors were evidenced for "treated" and "untreated" conditions, respectively.

![Bland-Altman analysis of the session1-session3 grading sessions.\
**2a**. Bulbar hyperaemia "treated". **2b**. Bulbar hyperaemia "untreated". **2c**. Limbal vascularization "treated". **2d**. Limbal vascularization "untreated". **2e**. Corneal staining "treated". **2f**. Corneal staining "untreated". Mean test-retest difference (solid line) and lower and upper limits of agreement are shown (discontinuous lines).](pone.0226960.g002){#pone.0226960.g002}

Discussion {#sec013}
==========

The type of bias described in this study may be included in the differential disease misclassification category, in that the disease is misclassified according to the actual disease status: Examiners are told on the third session that the condition is either "treated" or "untreated", and this leads to a misclassification of the status, in this case the grade they assign \[[@pone.0226960.ref019],[@pone.0226960.ref020]\]. Therefore, the initial hypothesis of the present study was that examiners would tend to award higher grades to conditions known to be left "untreated" than to "treated" conditions. In all sessions, examiners were instructed to grade 24 images (eight of each ocular condition under study) and were allowed 30 seconds per image. Efron and McCubbin noted better grading precision when observers were allowed 2 seconds to grade each image, but no further improvement was evidenced when grading time was extended to 60 seconds \[[@pone.0226960.ref025]\]. Therefore, a grading time of 30 seconds was considered sufficient.

Test-retest reliability, as explored with the ICC and Bland-Altman analysis, revealed a moderate (ICC values between 0.5 and 0.75) to good reliability (ICC between 0.76 and 0.9) for all conditions \[[@pone.0226960.ref026],[@pone.0226960.ref027]\], albeit results were inferior to those reported by other authors for bulbar hyperaemia \[[@pone.0226960.ref028],[@pone.0226960.ref029]\] and corneal staining \[[@pone.0226960.ref029]\] grading. Differences in grading procedure, type of reference grading scales and knowledge, training and experience of examiners may account for these discrepancies.

Within the same condition, grading reliability was independent of the severity of the condition, with similar individual ICC values and dispersion of data in the Bland-Altman plots. These results are in agreement with those reported by Efron and co-workers \[[@pone.0226960.ref015]\]. Interestingly, however, in general, higher ICC values were awarded to images displaying conditions located near the top or bottom thresholds of the grading scales. As noted by Bailey et al \[[@pone.0226960.ref018]\], scales with intrinsic upper and lower limits may lead to reduced data dispersion if conditions are near those limits. This phenomenon was particularly manifest for an image of limbal vascularization depicting a healthy eye (values of, or near 0) and for an image of severe corneal staining, which most examiners graded as 100 in the severity scale.

Average values for test-retest grading differences (0.2 for bulbar hyperaemia, 0.0 for limbal vascularization and -0.1 for corneal staining) did not evidence any bias between session 1 and session 2. In contrast, when comparing session 1 and session 3, a distinctive bias was found in which "treated" conditions were systematically awarded lower grades (-6.4 for bulbar hyperaemia, -4.5 limbal vascularization and -3.6 for corneal staining) and "untreated" conditions higher grades (5.3 for bulbar hyperaemia, 4.4 for limbal vascularization and 3.8 for corneal staining) than the same images at session 1 (**[Fig 3](#pone.0226960.g003){ref-type="fig"}**).

![Mean grading scores of the three sessions (session 3 shows scores for "treated" \[T\] and "untreated" \[NT\] images) for each condition (Bulbar hyperaemia: B; Limbal vascularization: L; Corneal Staining: C).](pone.0226960.g003){#pone.0226960.g003}

It must be acknowledged that, even if presenting statistical significance, grading bias resulting from "awareness of treatment" may not be considered as clinically significant. Indeed, the highest bias (-6.4 for "treated" bulbar hyperaemia) represents a change of -6.4%, with a change as small as -3.6% for "treated" corneal staining. Clinical significance may be defined as the smallest difference between two measures that would compel the clinician to modify his or her decision concerning the management of the patient. Further research is required to determine the threshold of clinical significance associated with changes in the severity of the various ocular conditions in which subjective grading is commonly implemented. It is interesting to note, however, that this study used a modified version of the Efron scale, presented as a continuous vertical line ranging from 0 mm (healthy eye) to 100 mm (highest possible grade), in contrast to the typical 4 or 5-steps scales commonly employed in clinical practice. Previous researchers have observed that continuous scales are associated with higher grading precision than discrete scales \[[@pone.0226960.ref018],[@pone.0226960.ref029]\]. It may be relevant to explore the actual effect of "awareness of treatment" when using a discrete scale in which a 1-step difference may represent a 20 or 25% change in grading.

The current study was not devoid of limitations. Firstly, only three typical ocular conditions were assessed. It would be interesting to explore grading bias with an assortment of images depicting conditions offering various degrees of grading challenge to the examiners. Secondly, experience, knowledge and training of the current study sample of students was limited and relatively homogeneous, and not necessarily representative of the whole population of ocular health providers. Indeed, assessing bias in a group of students with inferior skills may increase the effect of the bias (they may be more sensitive to the suggestion of "treated" vs "untreated"), which may artificially inflate the results. Finally, grading was conducted under strictly controlled conditions (time, type of grading scale, image presentation and parameters, etc.) which may not reflect the challenge encountered in grading real-life conditions in a clinical setting. Therefore, findings of this study must be interpreted with caution in views of its limited ecological validity.

In conclusion, many sources of bias have been reported to influence grading precision and reliability. The present findings revealed a statistically significant bias, referred to as "awareness of treatment", in which examiners with moderately reliable grading skills tended to award higher grades to "untreated" conditions and lower grades to "treated" conditions. As the study was designed, with very homogeneous characteristics in sample and grading conditions, the clinical significance of this source of bias could not be considered as manifestly superior to the normal range of variation found when making successive judgments of the same image.

10.1371/journal.pone.0226960.r001
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79-81: What is the difference between having an advanced knowledge of contact lens complications (high intensity) and having been additionally trained in ocular pathology (specificity)? Seems that these would be the same thing.

82: ....the Brien Holden......

92: "The aim of the present study......explore additional sources of bias....". The Introduction is unsatisfactory because, while it discusses some aspects of using grading scales (intra- and inter- user variability, tendency to use increments etc.), it does little to explain how the outcomes might be subject to bias. Thus, the suggestion here that the aim of this study is "exploring additional sources of bias" is unconvincing. Variability and bias are different phenomena and in the context of this manuscript, the Introduction should be focused on the latter rather than the former.

92: Is the term \"awareness of disease progression\" the most appropriate to describe what is being assessed here? What the graders are being told is whether that eye has been treated or not. They do not know anything about how the disease is progressing, just that someone has done something. Consequently the title of the paper may be misleading and should be changed.

102-109: Please verify that informed consent was obtained from participants.

Did you inform the participants that they should attempt to carry out the grading according to the scale provided and irrespective of the label on the images? This is an important factor as conscious bias may be more pronounced than unconscious bias.

In general, the statistical analysis seems overly complicated to achieve the stated aims. Bland & Altman (Bland and Altman 1999) have given clear guidelines on how to investigate these issues and as these methods are being used (though without appropriate citations, please add), it isn't obvious why additional and more convoluted analyses are necessary. For any given condition (or all conditions combined) all that is needed to test the hypothesis that treatment knowledge affects grading scores is:

i\. First, show that the first two repeats (R1 and R2) are unbiased, i.e. the mean difference (R1-R2), for all observers, is not significantly different from zero.

ii\. Second, show that the third repeat (R3) is significantly biased, by demonstrating that the mean differences (R1-R3) and/or (R2-R3) are significantly different from zero.

Both i) and ii) above can be achieved by observing the 95% confidence interval for the mean differences and inspection of the scatter of points in the plots may add additional insight. It isn't clear what extra value is offered by ANOVA, correlation, ICCs etc., so these procedures need to be clearly justified, if they are to be included.

191: Why is the precision quoted for limbal vascularization different from the other features (integer vs one decimal place)?

191-194: Can you explain what the difference is between "test-retest differences" and test-retest discrepancy"? These sound like the same thing, but as the SDs being quoted are different, presumably they are not? Is the "average value of the test-retest differences" not the same as the "average value for the test-retest discrepancy distribution"? Some elaboration and clarification is required.

246-267: This section appears to have nothing to do with the study data or outcomes. Please consider deleting it to shorten the text.

268-289: Likewise, this section repeats information already given elsewhere in the manuscript and can be deleted.

344-351: Although this is presented as the Conclusion, most of the text does not rely on or "conclude" from data presented in the manuscript. For example, the text between lines 344 and 348 makes a series of unrelated statements about clinical practice. Please revise to ensure conclusions are relevant and meaningful.

The use of the word "novel' at lines 94 and 348 is unreasonable and should be deleted. Types of bias have always existed, it is only our awareness of them that is new.

Check Ref 11: Spelling of Downie.

Bland, J Martin, and Douglas G Altman. 1999. \'Measuring agreement in method comparison studies\', Statistical Methods in Medical Research, 8: 135-60.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

19 Sep 2019

Manuscript No.: PONE-D-19-17494

Title: Awareness of disease progression: a source of bias in subjective grading of ocular complications

PLOS ONE

All changes are marked in red in the manuscript. We would like to use this opportunity to express our gratitude to the reviewers for their comments and suggestions, with which we believe our revised manuscript has been improved.

Academic Editor

Please address all reviewers' comments below, including the following issues:

1\. The background of the study is not clearly described in the Introduction. How does \'bias\' differ from \'variability in grading\'? Bias needs to be clearly defined and its sources detailed in the Introduction. There is a recent article on philosophical bias which the authors could also refer to in their deliberations on this area (Andersen et al. eLife 2019;8:e44929. DOI: <https://doi.org/10.7554/eLife.44929>). This article also notes the Catalogue of Biases (<https://catalogofbias.org/about/>) which is useful in the context of the current study.

ANSWER: Thank you for this comment and for providing us with very relevant sources of information to better address the subject of bias. We have edited our introduction extensively to describe with more detail and thoroughness the background of the study.

2\. The concept of bias is not novel, but rather more appreciated within the clinical and scientific community (see point 1. above).

ANSWER: Indeed, we have attempted to provide a better description of relevant sources of bias. In addition, we have removed the term "novel" from the manuscript.

3\. Please revise the title. The participants are not given details on disease progression, but rather images with descriptors of \'treated\' and \'not treated\'. The study is thus addressing the impact of awareness of treatment.

ANSWER: We have changed the title to: "Awareness of treatment: a source of bias in subjective grading of ocular complications".

4\. Please confirm that consent from the participants was given, and also provide the IRB number in the text.

ANSWER: Consent was obtained from all participants of the study. The IRB details are provided in the text.

5\. Please see Reviewer 2 comments regarding the statistics used in this study. These comments must be addressed.

ANSWER: We have revised our statistical analysis and removed those parts that were redundant in accordance to the suggestions of Reviewer 2.

6\. All participants were students within an Optometry program, and as noted in the Discussion, this limits the real-world relevance of the study. This issue should be emphasised in the Discussion.

ANSWER: Although this limitation of our study was already stated in the original manuscript, we have stressed the relevance of this issue.

7\. There are sections in the Discussion that do not directly relate to the current study (see Reviewer 2). Please review these and remove irrelevant sections.

ANSWER: As suggested by Reviewer 2, we have removed the irrelevant sections from the discussion of the manuscript.

We noticed you have some minor occurrence of overlapping text with the following previous publication, which needs to be addressed: Cardona, Genís, and Carme Serés. \"Grading contact lens complications: the effect of knowledge on grading accuracy.\" Current eye research 34.12 (2009): 1074-1081. In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

ANSWER: We have reviewed the text to identify and address all occurrences of overlapping with the previous publication. In addition, we have provided additional references to the text as appropriate.

Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If the need for consent was waived by the ethics committee, please include this information

ANSWER: We have provided these details in the manuscript and in the online submission information. In the revised manuscript, we have added the following: "Written informed consent was provided by all participants after the nature of the study was explained to them. In this regards, at the start of the study, subjects were only informed that they would be participating in three grading sessions. It was only following the conclusion of the third grading session that the full purpose of the study was explained, including the partial deceit required for the third grading session."

We note that Figure 1 in your submission contains copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission.

ANSWER: We contacted the publisher (Elsevier) and asked permission to publish Figure 1 under the CC BY 4.0 licence. As the book in which the images appear is published on <http://www.sciencedirect.com/>, we were automatically instructed the following:

• Locate the publication containing your desired content on <http://www.sciencedirect.com/science/jrnlallbooks>

• Click on the article/chapter name to access the abstract

• Below the author details, click "Get Rights and Content"

• The Rightslink request page will then be launched (please disable your pop-up blocker)

• Select the way you would like to reuse the content

• Create a Rightslink account if you haven't done so already

• Accept the terms and conditions and you're done

Whereupon, the corresponding fee to use the image was determined. After careful consideration, we decided to remove Figure 1 from the submission. We have edited the text accordingly.

Reviewer \#1

General Comments

1\) There is the possibility of an order effect, as the labelled images were only presented on the final session. The lack of an appropriate control group which did not have labelled images in the third session make reaching conclusive conclusions regarding the observed change difficult with this as a confound.

ANSWER: The concern of the reviewer is reasonable and adding a control group to the study would have been interesting. Unfortunately, this is no longer possible. However, we believe that, by conducting three grading sessions we partly covered the possible handicap of lacking a control group. Indeed, our findings revealed a moderate to good grading reliability of our participants, when comparing the first and second grading sessions, with no evidence of bias towards higher or lower grades. It was only on the third grading session that a noticeable bias was observed, in which "treated" conditions were consistently awarded lower grades and "untreated" conditions consistently received higher grades than in previous grading sessions. Although we acknowledge that other confounding factors may be at play, we believe it is reasonable to accept the hypothesis that the observed, and consistent, positive or negative bias, originated in the actual "awareness of treatment". Otherwise, we would have difficulty in interpreting how the order of grading sessions could lead to such consistent findings.

2\) The modification of the grading scale from an Ordinal/Discreet scale to one that is a more interval based one using a vertical visual analogue scale. This is different that what the scale would be used for clinically, so discussion on the impact of this modification and thus the output data which was evaluated (on a 100 point scale rather than a 0-4 scale) needs to be discussed

ANSWER: Although this issue was already briefly addressed in the original manuscript, we have elaborated on the discussion of the possible differences between a continuous 100-point scale and a 0-4 discrete scale. The new paragraph reads as follows: "It is interesting to note, however, that this study used a modified version of the Efron scale, presented as a continuous vertical line ranging from 0 mm (healthy eye) to 100 mm (highest possible grade), in contrast to the typical 4 or 5-steps scales commonly employed in clinical practice. Previous researchers have observed that continuous scales are associated with higher grading precision than discrete scales \[18,27\]. It may be relevant to explore the actual effect of "awareness of treatment" when using a discrete scale in which a 1-step difference may represent a 20 or 25% change in grading."

3\) The use of deception if used typically requires a debrief of subjects after the experiment has concluded, but no details regarding if subjects were debriefed after the study was concluded has been discussed or detailed

ANSWER: The reviewer is correct. We have added the following to the Subjects section of the revised manuscript: "Written informed consent was provided by all participants after the nature of the study was explained to them. In this regards, at the start of the study, subjects were only informed that they would be participating in three grading sessions. It was only following the conclusion of the third grading session that the full purpose of the study was explained, including the partial deceit required for the third grading session."

Specific Comments

Ethics Statement -- Incomplete (no ethics number and type of consent has been detailed)

ANSWER: This information is provided in the revised manuscript.

Introduction

\- Line 47 -- change "optometrist" to "optometrists"

\- Line 60 -- Remove "Beside" at the beginning of this sentence

ANSWER: Thank you. We have edited the text.

Methods

\- How do the authors propose to deal with the confound of the order effect? The changes being seen in the grading may be due to the labelling but may also be due to the learning due to the third test scenario. This could have been alleviated with the use of a control group which did not see these labels, or by randomizing the session where the labels were presented

ANSWER: Please refer to the response provided in the general comments.

\- Deception: How were subjects debriefed as to the nature and purpose of the deceit?

ANSWER: Please refer to the response provided in the general comments.

\- What is the impact of using the vertical analogue scale in conjunction with the Efron scale? The Efron scale is an ordinal scale, but the vertical analogue scale converts this to an interval scale which defines the differences between the grades to a certain value (a distance on the scale in this instance). As such, the grading is not exactly the same as grading using simply the Efron scale would be, which only has 5 discreet choices which can be made.

ANSWER: Please refer to the response provided in the general comments.

Reviewer \#2

Comments are given in the order they occur in the manuscript

60-62: Citations required.

ANSWER: We have added citations to this sentence.

65: Subjective grading of ocular complications is a complex process involving the comparison of real live images, provided by the slit-lamp....

i\. Isn\'t grading a relatively simple process for the observer? Although the neurological processing involved is undoubtedly complex, it occurs in the background without the observer's awareness. The whole point of grading systems is that they are simple for clinicians to use, compared to the alternatives.

ii\. \....comparison of real-life images, obtained using a slit lamp......

ANSWER: We have replaced "complex" with "relatively simple". Also, we have edited the sentence as suggested.

67-72: This is a very complex, composite sentence that is difficult to understand. Can it be simplified?

ANSWER: We have edited and simplified this sentence.

79-81: What is the difference between having an advanced knowledge of contact lens complications (high intensity) and having been additionally trained in ocular pathology (specificity)? Seems that these would be the same thing.

ANSWER: This refers to a previous research effort by some of the authors of the present study (Cardona G, Serés C. Grading contact lens complications: the effect of knowledge on grading accuracy. Curr Eye Res. 2009;34:1074-1081). The basis for that study originated in the syllabus implemented in our BSc in Optics and Optometry. In this regards, the course in ocular pathology provided students with knowledge on ocular health and disease, irrespective of whether or not the ocular condition was related to contact lens wear. On the other hand, during the three progressively advanced contact lens courses students were trained to diagnose, grade and manage complications caused by contact lens wear. A student having completed only the ocular pathology course may diagnose a certain ocular complication, but may not be able design an appropriate management strategy if the complication is associated with contact lens wear. Similarly, a student having completed only the contact lens courses will be able to offer a progressively better diagnose, grade and management of the contact lens related complication, but will lack the pathophysiological background to place the condition in the proper context. We believed that the effect of both aspects, although with a moderate amount of overlapping, could be studied independently.

82: ....the Brien Holden......

ANSWER: Thank you. We have edited the text.

92: "The aim of the present study......explore additional sources of bias....". The Introduction is unsatisfactory because, while it discusses some aspects of using grading scales (intra- and inter- user variability, tendency to use increments etc.), it does little to explain how the outcomes might be subject to bias. Thus, the suggestion here that the aim of this study is "exploring additional sources of bias" is unconvincing. Variability and bias are different phenomena and in the context of this manuscript, the Introduction should be focused on the latter rather than the former.

ANSWER: We have edited the Introduction section of the manuscript extensively to better address the topic of the current research. Thank you for your comment.

92: Is the term \"awareness of disease progression\" the most appropriate to describe what is being assessed here? What the graders are being told is whether that eye has been treated or not. They do not know anything about how the disease is progressing, just that someone has done something. Consequently the title of the paper may be misleading and should be changed.

ANSWER: The reviewer is correct. We have replaced "awareness of disease progression" with "awareness of treatment", both in the tittle of the manuscript and elsewhere in the body of the text.

102-109: Please verify that informed consent was obtained from participants.

ANSWER: We have added this information to the Subjects section of the revised manuscript: "Written informed consent was provided by all participants after the nature of the study was explained to them. In this regards, at the start of the study, subjects were only informed that they would be participating in three grading sessions. It was only following the conclusion of the third grading session that the full purpose of the study was explained, including the partial deceit required for the third grading session. "

Did you inform the participants that they should attempt to carry out the grading according to the scale provided and irrespective of the label on the images? This is an important factor as conscious bias may be more pronounced than unconscious bias.

ANSWER: Participants were not specifically directed to the need to grade images without paying attention to the label on the images, that is, the actual relevance of the label within the purpose of this study was not highlighted. Participants were informed that they should grade images as they had done in the previous two sessions, with the only difference that in the third session images corresponded to "treated" or "untreated" conditions. Thus, we believe that bias was unconscious. We have provided more information in the revised manuscript.

In general, the statistical analysis seems overly complicated to achieve the stated aims. Bland & Altman (Bland, J Martin, and Douglas G Altman. 1999. \'Measuring agreement in method comparison studies\', Statistical Methods in Medical Research, 8: 135-60) have given clear guidelines on how to investigate these issues and as these methods are being used (though without appropriate citations, please add), it isn't obvious why additional and more convoluted analyses are necessary. For any given condition (or all conditions combined) all that is needed to test the hypothesis that treatment knowledge affects grading scores is:

i\. First, show that the first two repeats (R1 and R2) are unbiased, i.e. the mean difference (R1-R2), for all observers, is not significantly different from zero.

ii\. Second, show that the third repeat (R3) is significantly biased, by demonstrating that the mean differences (R1-R3) and/or (R2-R3) are significantly different from zero.

Both i) and ii) above can be achieved by observing the 95% confidence interval for the mean differences and inspection of the scatter of points in the plots may add additional insight. It isn't clear what extra value is offered by ANOVA, correlation, ICCs etc., so these procedures need to be clearly justified, if they are to be included.

ANSWER: We would like to express our gratitude to the reviewer for this comment. We acknowledge that the statistical analysis was too complicated and redundant. Therefore, we have simplified it by deleting one of the two calculations of grading reliability (see response below), as well as the ANOVA and post-hoc analysis of differences in grading reliability amongst conditions (certainly not relevant for the purpose of the study). We have opted not to remove the intraclass correlation analysis, as this is useful to determine whether participants offered reliable grades, when comparing session 1 and session 2. Non-reliable grades between these two sessions would probably not recommend further analysing the performance of these participants. In addition, we have provided the 95% confidence intervals for the mean differences between grading sessions. Finally, we have added the needed reference to the Bland and Altman paper.

191: Why is the precision quoted for limbal vascularization different from the other features (integer vs one decimal place)?

ANSWER: We have corrected this error. All precision values are quoted with one decimal place in the revised manuscript. The correct value for limbal vascularization is 0.0.

191-194: Can you explain what the difference is between "test-retest differences" and test-retest discrepancy"? These sound like the same thing, but as the SDs being quoted are different, presumably they are not? Is the "average value of the test-retest differences" not the same as the "average value for the test-retest discrepancy distribution"? Some elaboration and clarification is required.

ANSWER: It is easier to explain it with an example. Average values for test-retest grading differences were 0.2 ± 1.8 (mean ± SD) for bulbar hyperaemia. On the other hand, SD and 95% confidence intervals of the test-retest discrepancy distributions were ±4.2 (±3.7 to ±4.7) for bulbar hyperaemia. As we had 8 images of bulbar hyperaemia and 30 participants, to determine the first set of values (0.2 ± 1.8), we calculated the mean (session 1-session 2) of the 8 images for each participant, and then we calculated the mean and SD of this value including all participants (n=30). This gave us the mean and SD of the differences between session 1 and session 2 for each condition and all participants. Similarly, for the second set of values \[±4.2 (±3.7 to ±4.7)\], we obtained the mean and 95% confidence intervals of the 30 values of SD obtained from the 8 differences between session 1 and session 2. According to (Efron N, Morgan PB, Jagpal R. The combined influence of knowledge, training and experience when grading contact lens complications. Ophthalmic Physiol Opt. 2003;23:79-85) the widespread of this second set of values gives an indication of grading reliability, with smaller values of SD denoting better reliability.

As reliability was also explored with the intraclass correlation coefficient (ICC), we have opted to delete part of this information: it is a potentially confusing and redundant estimation of grading reliability. In addition, we have edited the text accordingly.

246-267: This section appears to have nothing to do with the study data or outcomes. Please consider deleting it to shorten the text.

268-289: Likewise, this section repeats information already given elsewhere in the manuscript and can be deleted.

ANSWER: We have edited the Discussion of the manuscript to avoid redundancy and to remove irrelevant sections.

344-351: Although this is presented as the Conclusion, most of the text does not rely on or "conclude" from data presented in the manuscript. For example, the text between lines 344 and 348 makes a series of unrelated statements about clinical practice. Please revise to ensure conclusions are relevant and meaningful.

ANSWER: We have edited the Conclusions section of the manuscript as follows: "In conclusion, many sources of bias have been reported to influence grading precision and reliability. The present findings revealed a statistically significant bias, referred to as "awareness of treatment", in which examiners with moderately reliable grading skills tended to award higher grades to "untreated" conditions and lower grades to "treated" conditions. Further research is required to investigate the clinical significance of this source of bias, particularly given the confined characteristics of the sample and grading conditions of this study."

The use of the word "novel' at lines 94 and 348 is unreasonable and should be deleted. Types of bias have always existed; it is only our awareness of them that is new.

ANSWER: We have removed the term "novel" from the manuscript.

Check Ref 11: Spelling of Downie.

ANSWER: Thank you for pointing this typo to us. We have edited the text.
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15 Oct 2019

PONE-D-19-17494R1

Awareness of treatment: a source of bias in subjective grading of ocular complications

PLOS ONE

Dear Dr Cardona,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

The authors have addressed many of the issues raised in the earlier reviews, however there arel a few issues that remain to be resolved.

1\. How were the Intraclass Correlation Coefficients calculated, and are these necessary given repeats one and two were analysed; please justify the use of this analysis. 

2\. Please report all data with significant decimal places that relates or reflects the precision of the measurement being taken. For example, grading scales to 2 significant places does not reflect the precision of grading scales *per se.*

3\. Please address the issue of the practical and clinical significance of the overall study findings (Reviewer 2).

==============================

We would appreciate receiving your revised manuscript by Nov 29 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michele Madigan

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: I thank the authors for their responses and have the following further comments.

As this paper is about bias, I wonder whether ICC statistics add any useful information. I agree that establishing repeatability by comparing R1 and R2 is an important step, however aren't the mean difference between R1 and R2 and the LOAs sufficient to do this? If the authors insist on quoting ICCs, they should specify that the correlations are being calculated between R1 and R2. (lines 173-185). Also presumably ICCs were calculated for each image? Please clarify.

There is still some inconsistency in precision. LOA values have 2 decimal places as quoted and ICC values have three. Note that the point here is not that they should all be the same, but that they reflect what is reasonable to expect from the characteristics of the measurement. How precise can a subjective grading instrument really be?

I am very confused by the response concerning the distinction between "test-retest differences" and "test-retest discrepancy". You say "As we had 8 images of bulbar hyperaemia and 30 participants, to determine the first set of values (0.2 ± 1.8), we calculated the mean (session 1-session 2) of the 8 images for each participant, and then we calculated the mean and SD of this value including all participants (n=30). This gave us the mean and SD of the differences between session 1 and session 2 for each condition and all participants. Similarly, for the second set of values \[±4.2 (±3.7 to ±4.7)\], we obtained the mean and 95% confidence intervals of the 30 values of SD obtained from the 8 differences between session 1 and session 2." But is it not true that, in general, the grand mean of a data set is invariant to the order in which the columns and rows are averaged? In other words, it shouldn\'t matter if you average first across the 8 images and then over the 30 participants, or the other way around, the mean (though not the SD) will be the same. Why then, are there two different mean values quoted here?

In choosing Bland Altman plots to show the data it might help readers see the differences being reported if the same Y-axis scale were used for the treated vs untreated data. Actually, a simple bar chart might be even easier to understand (one bar each for R1, R2 and R3 treated R3 untreated).

One final comment is that the quoted difference between R1 and R3 (lines 193-197) all seem to be well within the LOAs for R1 vs R2, irrespective of "treatment" bias. This could reasonably be interpreted to suggest that the typical amount of bias introduce by treatment knowledge is smaller than the normal range of variation found when making successive judgments of the same image. What does this mean for the practical significance of the findings as well as the conclusion that "...more research is needed to investigate the clinical significance."? Is there not sufficient evidence here to conclude that the effect is unlikely to be of clinical significance?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

27 Nov 2019

Manuscript No.: PONE-D-19-17494R1

Title: Awareness of treatment: a source of bias in subjective grading of ocular complications

PLOS ONE

All changes are marked in red in the manuscript. We would like to thank the reviewer for their constructive and positive comments to our manuscript.

Academic Editor

1\. How were the Intraclass Correlation Coefficients calculated, and are these necessary given repeats one and two were analysed; please justify the use of this analysis.

2\. Please report all data with significant decimal places that relates or reflects the precision of the measurement being taken. For example, grading scales to 2 significant places does not reflect the precision of grading scales per se.

3\. Please address the issue of the practical and clinical significance of the overall study findings (Reviewer 2).

ANSWER: Dear Academic Editor, we have addressed these concerns according to the comments and suggestions of the reviewer (please refer to the responses provided below).

Reviewer \#2

I thank the authors for their responses and have the following further comments.

As this paper is about bias, I wonder whether ICC statistics add any useful information. I agree that establishing repeatability by comparing R1 and R2 is an important step, however aren't the mean difference between R1 and R2 and the LOAs sufficient to do this? If the authors insist on quoting ICCs, they should specify that the correlations are being calculated between R1 and R2. (lines 173-185). Also presumably ICCs were calculated for each image? Please clarify.

ANSWER: We have edited the Data Analysis section of the manuscript to better describe how ICC values were calculated: "Intraclass correlation coefficients (ICC) (two-way mixed effects, absolute agreement, multiple examiners/measurements model) of session 1 and 2 (test-retest) were calculated to determine grading reliability for each image and the corresponding median and range (minimum-maximum) of values for each ocular condition (comprised of 8 images) was determined". Even if redundant, we have also added this information to the Results section.

We believe that ICC values are relevant, as they provide an estimation of reliability with a single numerical value that can be compared with published normative data. The Bland-Altman analysis, on the other hand, is very useful in showing the actual distribution of the differences between two measurements, and highlighting any possible bias. We agree with the reviewer that both analyses provide information about reliability, but we believe that this information is not redundant, but complementary. If the reviewer considers that it is indeed unnecessary, however, we would not oppose deleting the ICC analysis from the manuscript.

There is still some inconsistency in precision. LOA values have 2 decimal places as quoted and ICC values have three. Note that the point here is not that they should all be the same, but that they reflect what is reasonable to expect from the characteristics of the measurement. How precise can a subjective grading instrument really be?

ANSWER: The reviewer is correct. We have attempted to be consistent with the number of significant digits throughout the manuscript. Thus, we have followed the recommendations of \[Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155-163\] and \[Liljequist D, Elfving B, Roaldsen KS. Intraclass correlation -- A discussion and demonstration of basic features. PLoS One. 2019;14:e0219854\], as well as of \[<https://labwrite.ncsu.edu/res/gh/gh-sigdig.html>\], and reported ICC values to two significant digits (such as 0.80 or 0.75) and subjective grading scores to one significant digit, that is, the tenths digit (such as 23.0 or 19.2). We have added the reference \[Liljequist D et al\] to our manuscript.

I am very confused by the response concerning the distinction between "test-retest differences" and "test-retest discrepancy". You say "As we had 8 images of bulbar hyperaemia and 30 participants, to determine the first set of values (0.2 ± 1.8), we calculated the mean (session 1-session 2) of the 8 images for each participant, and then we calculated the mean and SD of this value including all participants (n=30). This gave us the mean and SD of the differences between session 1 and session 2 for each condition and all participants. Similarly, for the second set of values \[±4.2 (±3.7 to ±4.7)\], we obtained the mean and 95% confidence intervals of the 30 values of SD obtained from the 8 differences between session 1 and session 2." But is it not true that, in general, the grand mean of a data set is invariant to the order in which the columns and rows are averaged? In other words, it should not matter if you average first across the 8 images and then over the 30 participants, or the other way around, the mean (though not the SD) will be the same. Why then, are there two different mean values quoted here?

ANSWER: As suggested by the reviewer and noted in the previous responses to the reviewers "As reliability was also explored with the intraclass correlation coefficient (ICC), we have opted to delete part of this information: it is a potentially confusing and redundant estimation of grading reliability", this information was considered redundant and deleted from the revised manuscript (R1).

Aiming at clarifying this issue, we agree with the reviewer that the grand mean of a data set is invariant to the order in which columns and rows are averaged. However, please note that the set of values \[±4.2 (±3.7 to ±4.7)\] did not correspond to the grand mean of grading scores (that is, 8 images per 30 participants) but to the mean (of the 30 participants) of the SD obtained from the differences between R1 and R2 of each condition (set of 8 images) and participant.

In choosing Bland Altman plots to show the data it might help readers see the differences being reported if the same Y-axis scale were used for the treated vs untreated data. Actually, a simple bar chart might be even easier to understand (one bar each for R1, R2 and R3 treated R3 untreated).

ANSWER: Thank you. For clarity, we have added a bar chart figure displaying all results in the same scale (Figure 3).

One final comment is that the quoted difference between R1 and R3 (lines 193-197) all seem to be well within the LOAs for R1 vs R2, irrespective of "treatment" bias. This could reasonably be interpreted to suggest that the typical amount of bias introduce by treatment knowledge is smaller than the normal range of variation found when making successive judgments of the same image. What does this mean for the practical significance of the findings as well as the conclusion that "...more research is needed to investigate the clinical significance."? Is there not sufficient evidence here to conclude that the effect is unlikely to be of clinical significance?

ANSWER: The reviewer highlights an important issue. We have further addressed the clinical significance of our findings in the Discussion section of the manuscript (and edited the conclusions of the abstract). The conclusion of the revised manuscript is as follows: "In conclusion, many sources of bias have been reported to influence grading precision and reliability. The present findings revealed a statistically significant bias, referred to as "awareness of treatment", in which examiners with moderately reliable grading skills tended to award higher grades to "untreated" conditions and lower grades to "treated" conditions. As the study was designed, with very homogeneous characteristics in sample and grading conditions, the clinical significance of this source of bias could not be considered as manifestly superior to the normal range of variation found when making successive judgments of the same image."
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Dear Dr. Cardona,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Michele Madigan

Academic Editor
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Dear Dr. Cardona:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michele Madigan

Academic Editor

PLOS ONE
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